Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445400 | 0.71 | CHRM2 (0.62) | GPR119KDM4EPKM | |
| SCHEMBL5349149 | 0.68 | UTS2R (0.45) | GPR119UTS2RKDM4EPKM | |
| SCHEMBL8825578 | 0.67 | ACHE (0.64) | GPR119KDM4EPKM | |
| SCHEMBL29890980 | 0.67 | ACHE (0.64) | GPR119KDM4EPKM | |
| SCHEMBL6150378 | 0.67 | BACE1 (0.51) | GPR119DDB1CRBNKDM4EPKM | |
| SCHEMBL8445327 | 0.66 | GPR119 (0.48) | GPR119KDM4EPKM | |
| SCHEMBL29554785 | 0.65 | KDM4E (0.45) | GPR119DDB1CRBNKDM4EPKM | |
| SCHEMBL28901610 | 0.65 | KDM4E (0.45) | GPR119DDB1CRBNKDM4EPKM | |
| SCHEMBL31161656 | 0.65 | GPR119 (0.54) | GPR119KDM4EPKM | |
| SCHEMBL25582890 | 0.65 | CRBN (0.54) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | GPR119 2191/4885P2RX7 4512/4885DDB1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.